# A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Study · id `cardio:ct-nct01785771` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01785771](<https://clinicaltrials.gov/study/NCT01785771>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01785771

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01785771. Allocation not applicable; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2018-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01785771, source copy `cardio:ctgov-nct01785771-2019-03-07`, retrieved 2026-10-26)
- Start date: 2013-05 (registry gives no type) (ClinicalTrials.gov record NCT01785771, source copy `cardio:ctgov-nct01785771-2019-03-07`, retrieved 2026-10-26)
- Primary completion: 2018-01 (actual) (ClinicalTrials.gov record NCT01785771, source copy `cardio:ctgov-nct01785771-2019-03-07`, retrieved 2026-10-26)
- Completion: 2018-01 (actual) (ClinicalTrials.gov record NCT01785771, source copy `cardio:ctgov-nct01785771-2019-03-07`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01785771, source copy `cardio:ctgov-nct01785771-2019-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01785771-2019-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
- Condition: Type 2 Diabetes
- Intervention (Drug): ITCA 650 (exenatide in DUROS)
- Lead sponsor: Intarcia Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Intarcia Therapeutics (`cardio:org-intarcia-therapeutics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study (`cardio:pubmed-29301824`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 867af78e2d0b4fcd28439867f96f5d5b54ab3a3a5b3b97ab22efc3681e741670
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
